Cannabidiol for the treatment of patients at a high-risk of psychosis

Phase 2

• Conditions: Clinical high-risk for psychosis (CHR); Mental and Behavioural Disorders; Clinical high-risk state for psychosis (CHR)

• Registration Number: ISRCTN10334895
• Lead Sponsor: King’s College London and South London and Maudsley NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-08-31
• Last Update Posted: 7 March 2022
• Study Completion: 2023-05-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1. Aged 18-35
2. Diagnosed with a clinical high-risk state for psychosis (CHR)
3. 'Attenuated psychotic symptoms' sub-group (CHR-APS) as defined using the CAARMS (Comprehensive Assessment of At-Risk Mental States) criteria

Exclusion Criteria

1. History of a previous psychotic or manic episode lasting 7 days or more
2. Neurological disorders (e.g. epilepsy) or severe intercurrent illness
3. Current treatment with psychotropic medication or previous treatment with antipsychotic medication for more than 7 days
4. IQ of less than 70
5. Females who are pregnant, lactating or not using contraception

Study & Design

• Study Type: Interventional
• Study Design: Not specified